Fabrication of copper molybdate nanoflower combined polymeric graphitic carbon nitride heterojunction for water depollution: Synergistic photocatalytic performance and mechanism insight

In the scope, developed a novel copper molybdate decorated polymeric graphitic carbon nitride (CuMoO4@g-C3N4 or CMC) heterojunction nanocomposite in an easy solvothermal environment for the first time. The synthesized CMC improved the photocatalytic degradation of an antibiotic drug [ciprofloxacin (CIP)] and organic dye [Rhodamine B (RhB)]. Consequently, the CMC demonstrates a marvelous crystalline nature with ∼26 nm size, as obtained from XRD analysis. Besides, the surface morphology studies confirm the large-scale construction of flower-like CMC with a typical size of 10-15 nm. The CMC showed efficient catalytic activity for both the pollutants, achieving the degradation of 98% for RhB and 97% for CIP in 35 and 60 min, respectively. The reaction parameters including the concentration of pollutants, catalyst dosages, and scavengers are optimized for the best photocatalytic results. Notably, the trapping tests showed that the •OH and O2•- radicals are the primary oxidative species liable for the photocatalytic process. The recyclability test of the photocatalyst infers that the photocatalyst is highly stable up to the fifth recycle. Our work affords an efficient and ideal path to constructing the new g-C3N4-based architected photocatalyst for toxic wastewater treatment in the near future.

The safety and efficacy of mycophenolate mofetil in children and adolescents with steroid-dependent nephrotic syndrome: a single-centre study

Background

Steroid-dependent nephrotic syndrome (SDNS) patients experience frequent relapse or adverse effects on long-term treatment with steroids or cyclophosphamide. This study assessed the efficacy and side effect profile of mycophenolate mofetil (MMF) therapy in children with nephrotic syndrome in our population.

Methods

A retrospective study was performed on children with SDNS who were on MMF therapy for a minimum period of 1 year, and were on regular follow-up in the Department of Nephrology at the Institute of Child Health and hospital for children attached to Madras Medical College.

Results

The study included 87 patients, with a male:female ratio of 2:1. The median age at diagnosis of nephrotic syndrome was 3 years [95% confidence interval (CI): 1–8 years], which was found to be a statistically significant risk factor for MMF failure. The median duration of follow-up after initiation of MMF therapy was 3 years and 3 months (95% CI: 1 year and 3 months to 6 years and 6 months). At initial evaluation, 31 (36%) patients presented with SDNS while the remaining had frequently relapsing nephrotic syndrome progressing to SDNS. Intravenous cyclophosphamide was used as first-line therapy in 82 patients, of whom 24 patients had persistent proteinuria while the remaining 58 had attained remission for a median duration of 6 months. The median duration of treatment with MMF was 2 years and 6 months (95% CI: 1 year and 3 months to 4 years and 6 months). MMF was used at a mean dose of 28.5 mg/kg. Seventy-two (83%) patients were MMF-sensitive, and these patients had a reduction in mean prednisolone dose from 1.28 to 0.35 mg/kg (P < 0.05). Among the MMF-sensitive patients, 31 had stopped MMF after a minimum period of 2 years, following which they had a median remission period of 5 months (95% CI: 1–8 months). MMF failure occurred in 15 (17%) patients. Adverse events were documented in 19 (22%) patients.

Conclusions

Continuous MMF therapy achieved remission in 83% of patients. MMF was well tolerated in the study population and discontinuation of MMF resulted in 100% relapse.